2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

MANAGEMENT OF T1 BREAST CANCERS
Table 1. T1ab N0 Breast Cancer Literature Review (Papers Published 2002–2011) (Cont’d)
Time %DFS
Measure of Efficacy
%RFS %DDFS %OS %IBTR Adverse Factors Comments HER2 Test
5 y 97.2 age � 35, TN 48% MRM IHC 3� (10%?)
96.8
98.5
92.6
5y HER2�, TN IHC 3� 10%
for N1�, multi,
HER2�, TN
or FISH
HR 7.2
�98
�92
�90 (HR 5.7) T1b TN DDFS �84%,
HR 5.5 �90 (HR 6)
HER2� �87%
5 y 85.6 N1, HER2�, TN 3 M1, 54 N1 (15%) IHC 3� 30%
or FISH
95.5 (HR 2.01)
97.4
HR 4.16 HER2, HR 3.37 TN
5y HER2�, ER-, grade 3,
DAKO 3�
97.2 premenopausal, LVI ER- 15%
or FISH
88 ER- 51%
5 y 94.2 96.5 2.9 1 cm tumors have 12.5% 5 y IHC 3� 10%
97.4 99.1
distant recurrence risk
or FISH
91.1 94
3y
99
89
83
IHC 3� 10%
or FISH
5y
97.7
IHC 3� or FISH
5y,
10yOS
90.5 T1b 79%
92.3 95.7 98.6 HER2� (HR 4.1 for DFS);
size for DDFS
5 y DFS HER2� 83.7% DAKO 3�
or FISH
83.7 89.9 83.3 ER- 39%
95.7 100 3.5 HER2 (but not OS)
85.1 99.2 14.9
3y More LVI, T1c in T-treated group IHC 3� or FISH
82 95 97
78 97 98
97 100 99
95 100 98
5y �96 if treated w/chemo/
trastuzumab
25% T1a; 3 pts trastuzumab alone
�86 if not treated Chemo given for ER-, G2-3,
high mitoses
5y TN 35% T1a
97.9
95.6 (HR 1.64)
93.5 (HR 3.13)
Abbreviations: Pt, patient; yrs, years; F/U, follow-up; mos, months; ER, estrogen receptor; HER, human epidermal growth factor receptor; OBS, observation; ET,
endocrine therapy; DFS, disease-free survival; RFS, recurrence-free survival; DDFS, distant disease-free survival; OS, overall survival; IBTR, ipsilateral breast tumor
recurrence; NSABP, National Surgical Breast and Bowel Project; unk, unknown; nd, not done; XRT, radiation therapy; HR, hazard ratio; Tam, tamoxifen; NR, not
reported; IHC, immunohistochemical; CISH, chromagen in situ hybridization; PR, progesterone receptor; LVI, lymphovascular invasion; SEER, Surveillance,
Epidemiology, and End Results; BCSM, breast cancer-specific mortality; LN, lymph node; ALND, axillary lymph node dissection; AA, African American; BC, breast
cancer; FISH, fluorescence in situ hybridization; T, tumor; SP3 Ab, SP3 antibody; MDACC, M. D. Anderson Cancer Center; TN, triple-negative; MRM, modified radical
mastectomy; BCS, breast cancer survival; CT, computed tomography; DAKO, DAKO, Inc.; MSKCC, Memorial Sloan-Kettering Cancer Center; KPNC, Kaiser Permanente
Northern California; ONCO, ONCO Languedoc-Roussillon Network.
15